CRPC – malecare.org

Duration of Response to Androgen Deprivation Therapy (ADT) and Efficacy of Secondary ADT, Docetaxel and Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer

Men who become castrate resistant in less than 12 months from starting androgen deprivation therapy (ADT) were found to have poor efficacy with a 2nd line of ADT. However, the development of early castrate resistance did not impair the benefit of any of the docetaxel based chemotherapy. Researchers examined the records of 132 consecutive men [...]

By Malecare|2017-10-19T10:48:30-04:00March 21st, 2014|2nd line hormone therapy, Advanced Prostate Cancer, Cabazitaxel, Drugs & Treatments, General Information, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments

Reported Antitumor Activity of MDV3100 in a Phase 1-2 Study of Advanced Prostate Cancer – A Great Success

At the on-going AUA Meeting, Dr. Howard Scher along with a collaborating group of medical oncologists reported their data from a Phase I-II trial of MDV3100 in castration-resistant prostate cancer (CRPC). […]

By Malecare|2017-10-19T10:54:00-04:00May 31st, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, MDV3100, On The Horizon, Research, Uncategorized, Understanding APC|1 Comment

Timing IADT, Can “On Cycle” Time Periods Predict Outcomes?

A study by Yu et al., of men with a rising PSA after failed radical prostatectomy or radiation therapy who were placed on intermittent androgen deprivation therapy (IADT) indicated that the length of their first “off cycle” correlates with their expected time to developing castrate resistant prostate cancer (CRPC) and to their prostate cancer-specific mortality. [...]

By Malecare|2020-02-04T11:37:55-05:00May 17th, 2010|Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Research, Uncategorized, Understanding APC|0 Comments